tbuckley/cabot-search huggingface dataset:
Abstract 15359: Cost-effectiveness of Different Strategies for the Diagnosis of Stable Coronary Artery Disease: Results from the Evinci Study
Authors: Giuseppe Turchetti, Valentina Lorenzoni, Stefania Bellelli, Francesca Pierotti, Daniele Rovai, Chiara Caselli, Stephan R Underwood, Juhani Knuuti, Danilo Neglia
Journal: Circulation (2014)

Introduction: In patients with suspected coronary artery disease (CAD) the comparative value of non invasive diagnostic imaging modalities or strategies is not yet defined. Hypothesis: We hypothesized that a comparative cost-effectiveness (CE) analysis of different non-invasive imaging strategies in a European population of patients with stable angina could identify the best approach for the diagnosis of significant CAD. Methods: In 475 pts (291 males, 60±9 yrs) with stable angina enrolled in the EVINCI multicenter study, CT coronary angiography (CTCA) and stress imaging were performed before invasive coronary angiography (ICA). Significant CAD was defined as &gt;50% stenosis in the left main or &gt;70% stenosis in a major coronary vessel or 30-70% stenosis with fractional flow reserve ≤0.8. Non-invasive imaging strategies included CTCA or stress imaging (ECHO, CMR, SPECT or PET) alone or in combination. Combinations were positive if both CTCA and the stress test were positive. CE analysis was performed using per patient data. Effectiveness was defined as percentage of correct diagnosis. Costs were calculated by country-specific reimbursements for each test considered plus ICA costs when non invasive tests were positive. Incremental cost-effectiveness ratios (ICERs) were obtained by regression analysis and using a propensity-score adjustment. Results: Significant CAD was diagnosed at ICA in 140 pts (29%). CTCA had the highest diagnostic performance among single imaging modalities and CTCA-PET among combinations (Table). At CE analysis, ECHO approach was the least costly but also the least effective, while CTCA alone or in combination with PET had increasingly higher effectiveness for a willingness to pay (WTP) exceeding 2,000 Euro and 5,000 Euro, respectively (Table). Conclusion: Stress ECHO is a cost-effective approach to diagnose stable CAD when the WTP is low. CTCA alone or combined with stress PET allows a more effective diagnostic workflow for higher WTP.
Prognostic factors in patients with malignant pleural effusion undergoing thoracoscopy
Authors: Stavros Anevlavis, Kailash Nath Gupta, Ioannis Sotiriou, George Kouliatsis, Argyris Tzouvelekis, Mihalis Koukourakis, Demosthenes Bouros, Marios Froudarakis
Journal: European Respiratory Journal (2011)

Background: Survival of patients with malignant pleural effusion is considered generally poor. These patients are likely to undergo thoracoscopy for diagnosis and treatment of their disease. Factors affecting survival are important to define, to decide whether patients should undergo interventional procedures. The aim of our study was to evaluate prognostic factors of patients with malignant pleural effusion undergoing thoracoscopy.

Methods: Patients with malignant origin proven by thoracoscopy, have been studied prospectively to determine prognostic factors. Survival time was defined as the time interval from thoracoscopy to death or last follow-up. A regression model was used to assess significant prognostic factors.

Results: 90 patients with histological diagnosis of malignant pleural effusion after thoracoscopy, were included. Diagnosis was: lung carcinoma 43%, breast carcinoma 23.6%, mesothelioma 12.9%, genito-urinary carcinoma 7.1%, GI 4.8%, other 5.1%, unknown primary 3.5%. The median overall survival time was 11 months ranging from 1 to 55. The Cox analysis showed that histology of the primary tumor (p=0.019), ps (p<0.001), gender (p=0.01), WBC (p=0.01) and neutrophils/lymphocytes ratio (p=0.018) were prognostic factors for survival. In the multivariate analysis, prognostic factors were histology (p=0.002), performance status (p<0.001) and WBC (p=0.01).

Conclusion: Performance status, histology of the primary tumor, and WBC are factors of survival in patients undergoing thoracoscopy for malignant pleural effusion. The prospective identification of patients meeting these criteria may help physicians select patients for interventional procedures.
Multifunctional role of the transcription factor Blimp-1 in coordinating plasma cell differentiation
Authors: Martina Minnich, Hiromi Tagoh, Peter Bönelt, Elin Axelsson, Maria Fischer, Beatriz Cebolla, Alexander Tarakhovsky, Stephen L Nutt, Markus Jaritz, Meinrad Busslinger
Journal: Nature Immunology (2016)
Abstract 279: A Deletion In The N2A Region Of Titin Carried By Muscular Dystrophy With Myositis (mdm) Mice Severely Affects Skeletal Muscle, But Not The Heart
Authors: Ida G Lunde, Hiroko Wakimoto, Michael A Burke, Wolfgang Linke, Geir Christensen, Jonathan G Seidman, Christine E Seidman
Journal: Circulation Research (2014)

20% of dilated cardiomyopathy patients carry mutations in the giant protein titin. Mutations are predominant in A band but also occur in I band, a domain that regulates passive tension and myocyte signaling. A recessive mouse mutation in titin I band N2A region (mdm) causes early onset muscular dystrophy with myositis and death. We assessed cardiac morphology, function, and transcriptional profiles (RNAseq) in mdm mice. Young homozygous mdm mice (n&gt;6) have reduced body weight (7gms) vs. heterozygous (20gm) or WT (17gm) littermates, with severe skeletal muscle dystrophy. Four-week old homozygous mdm mice have higher left ventricular (LV): body weight ratios. Echocardiography revealed thinner LV posterior wall and septum (LVPWd and IVSd) and normal LV diameter (LVDd); when normalized for body weight, cardiac dimensions were increased compared to WT or heterozygous mdm mice. Fractional shortening was reduced in homozygous Mdm mice (35%) vs. WT (40-41%, p&lt;0.01); histology showed neither overt pathology nor fibrosis. Titin gels showed lack of difference in cardiac titin isoform pattern, consistent with RNAseq, which showed the mdm titin transcript excluded exons 107 and 108, deleting in frame 48 amino acids. 240 transcripts (0.8%) were differentially expressed (fold change &gt;1.5 and &lt;0.75, p&lt;0.001) in homozygous vs. heterozygous mdm hearts; ANP and BNP were mildly upregulated (2- and 1.2-fold). Altered transcripts participated in extracellular and immune signaling pathways. Among titin binding partners, only calpain-3 that interacts with N2A was changed (0.6-fold), consistent with previous reports in skeletal muscle. As humans have heterozygous mutations, we stressed adult heterozygous mdm and WT mice (2 weeks of angiotensin II infusion): both had comparable hypertrophic responses (increased LVPWd and IVSd). Aged (89 week old) unstressed heterozygous mdm mice had normal cardiac dimensions and function. The N2A region, I-band titin mdm mutation causes minimal cardiac dysfunction in mice, unlike the severe skeletal muscle phenotype. Human I-band mutations are unlikely to cause dilated cardiomyopathy.
Histology of Early Reactions of Skin and Mucous Membrane of the Lip of the Mouse to a Single Application of a Carcinogen&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Barnet M. Levy, Robert Gorlin, Robert Gottsegen
Journal: JNCI Journal of the National Cancer Institute (1951)

Histology of Early Reactions of Skin and Mucous Membrane of the Lip of the Mouse to a Single Application of a Carcinogen Get access Barnet M. Levy, Barnet M. Levy Columbia University, School of Dental and Oral Surgery of the Faculty of Medicine, New York, N. Y. Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert Gorlin, Robert Gorlin Columbia University, School of Dental and Oral Surgery of the Faculty of Medicine, New York, N. Y. Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert Gottsegen Robert Gottsegen Columbia University, School of Dental and Oral Surgery of the Faculty of Medicine, New York, N. Y. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 12, Issue 2, October 1951, Pages 275–285, https://doi.org/10.1093/jnci/12.2.275 Published: 01 October 1951 Article history Received: 23 April 1951 Published: 01 October 1951
Hitchhiking and associative overdominance at a microsatellite locus.
Authors: M Slatkin
Journal: Molecular Biology and Evolution (1995)

The possible effects of a selected locus on a closely linked microsatellite locus are discussed and analyzed in terms of coalescent theory and models of the mutation process. Background selection caused by recurrent deleterious mutations will reduce the variance of allele size at a microsatellite locus. The occasional substitution of advantageous alleles (genetic hitchhiking) will also reduce the variance, but a high mutation rate at a microsatellite locus can restore the variance relatively rapidly. Overdominance at the selected locus will increase the variance at the microsatellite locus and create partitioning of the variation in allele size among gametes carrying one or the other of the overdominant alleles. These results suggest that neutral microsatellite loci can provide indicators of selective processes at closely linked loci.
Autologous peripheral-blood progenitor-cell support following high-dosechemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma.
Authors: G Marit, C Faberes, J L Pico, J M Boiron, J H Bourhis, P Brault, P Bernard, C Foures, P Cony-Makhoul, M Puntous, G Vezon, A Broustet, D Girault, J Reiffers
Journal: Journal of Clinical Oncology (1996)

PURPOSE The aims of the current study were to evaluate in patients with high-risk multiple myeloma (MM) the feasibility and usefulness of high-dose chemotherapy or chemoradiotherapy followed by hematopoietic stem-cell support with autologous peripheral-blood progenitor cells (PBPC) harvested after high-dose cyclophosphamide (HDCYC). PATIENTS AND METHODS Seventy-three patients with high-risk MM were entered onto the study. Before the procedure, all patients had received HDCYC to collect PBPC by leukapheresis. One patient died of infection after HDCYC. All other patients subsequently received high-dose melphalan (HDM) (140 mg/m2) either alone (n = 1) or associated with either busulfan (16 mg/kg; n = 4) or total-body irradiation (TBI) (8 to 15 Gy; n= 67). In addition, three of the latter patients received cyclophosphamide (120 mg/kg). Thereafter, PBPC were reinfused either alone in 61 patients or together with back-up bone marrow cells in 11 patients in whom the granulocyte-macrophage colony-forming unit (CFU-GM) cell content of the leukapheresis was low. RESULTS One patient died of acute cardiac failure after reinfusion of PBPC; three patients did not respond after autologous blood progenitor cell transplantation (ABPCT), while the other 68 patients achieved either a complete response (CR; n = 32) or partial response (PR; n = 36). Thirty-six patients relapsed or progressed after a median response duration of 14.5 months (range, 3 to 43) and 19 of these subsequently died. Four other patients died while still responsive of lung cancer (n = 1) or infection (n = 3). The remaining 28 patients are currently alive and still responding with a median follow-up duration of 27 months (range, 6 to 66). The 3-year probability of survival was 66% +/- 12% (95% confidence interval [CI] after ABPCT and 77% +/- 51% (95% CI) from diagnosis. CONCLUSION High-dose chemotherapy or chemoradiotherapy followed by autologous PBPC support in MM is feasible and efficient. Further studies are needed to confirm these encouraging, although preliminary, results and to compare this technique with other therapeutic strategies.
Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC)
Authors: J. Carlson, N. Oestreicher, D. P. Lubeck, S. D. Ramsey, D. L. Veenstra
Journal: Journal of Clinical Oncology (2007)

7664 Background: Multiple treatment strategies are now available for stage IIIB/IV non-small cell lung cancer (NSCLC) after failure of 1 st line treatment, but their relative economic and clinical value is not clear. Methods: We developed a health state transition model with 3 health states (progression free, disease progression, and death) to estimate the direct medical costs and quality-adjusted life-years (QALYs) of treating refractory NSCLC from the US healthcare system perspective. The treatments considered were erlotinib, docetaxel, and pemetrexed, and the time horizon was 2 years. Mean survival and progression free survival were assumed equal for all three treatments based on published pivotal clinical trials; side effect data were derived from the same studies. Utilities were obtained from a recent community-based study performed in the UK. Costs were obtained from published sources, and costs and effects were discounted at 3%. Sensitivity analyses were performed to evaluate uncertainty in the results. Results: Total costs in the base case were $31,000 for erlotinib, $33,700 for docetaxel, and $38,200 for pemetrexed. Drug acquisition and administration costs were $11,800, $12,200, and $18,700, respectively. Adverse event costs were $200, $2,500, and $500 on average per patient, and disease costs were equivalent at $19,000. QALYs were slightly greater for erlotinib versus docetaxel and pemetrexed (an increase of 0.02 and 0.01, respectively), due to differences in side effect profiles. The cost differences were robust to sensitivity analyses; when the utility for IV vs. oral therapy were assumed equal, erlotinib had 0.1 greater QALY than docetaxel and equivalent QALYs to pemetrexed. Conclusions: The results of our study suggest erlotinib in the treatment of refractory NSCLC in the United States is cost-saving compared with alternative treatments, with a slight improvement in patient quality of life. The results of ongoing comparative clinical trials will be useful for further evaluation of potential survival benefits. [Table: see text]
Clinical significance of prophylactic intrathecal chemotherapy in the treatment of glioblastoma multiforme
Authors: T. Iuchi, K. Hatano, T. Sakaida, S. Hirono
Journal: Journal of Clinical Oncology (2009)

e13022 Backgrounds: We previously have reported that hypo-fractionated high-dose irradiation (HdI; 68Gy/8F) showed excellent local control but no effect on prevention of cerebrospinal fluid dissemination (CSFd), resulted in limited efficacy on patients’ survival in glioblastoma (GBM). The aim of present analysis is to evaluate the clinical significance of prophylactic intrathecal administration of thiotepa (iT) in the treatment of GBM patients. Methods: Histologically confirmed GBMs without CSFd at diagnosis were enrolled. Patients were classified into four groups owing to the post-surgical treatment strategy as follows: Group A patients (n = 65) were treated by conventional radiotherapy (cRT; 60Gy/30F) alone; Group B patients (n = 17) were by cRT concurrent witn iT; Group C patients (n = 28) were by HdI alone; Group D patients (n = 30) were by HdI concurrent with iT. In Group B and D, Ommaya reservoir was placed into the lateral ventricle and 10mg of thiotepa was administrated weekly after surgery for five times. The local progression-free survival (PFS), CSFd-free survival (CFS), and overall survival (OS) were compared in these four groups. Results: Group C and D patients showed significantly longer PFS than Group A and B (p &lt; 0.0001), suggesting the clinical significance of HdI for local control of this tumor. On the other hand, CFS in Group B and D was significantly longer than that in Group A and C (p = 0.049), demonstrating the effect of iT for prevention of CSFd. However, significant improvement of OS on the conventional treatment (Group A, median OS: 12.3 months) was observed only in Group D (median OS: 30.2 months, p = 0.002) and not in Group B or C (24 months, p = 0.135, and 14.9 months, p = 0.481 respectively). Conclusions: These data indicated that both of local control and prevention of CSFd were required for better survival of patients with GBM, and iT concurrent with HdI may be one of the treatments that fill these requirements. No significant financial relationships to disclose.
腹胀-消瘦-胶冻样腹水
Authors: 赵喆, 沈敏, 王迈, 曾学军
Journal: BMJ (2009)

患者女，73岁，因“腹胀、腹围增大2个月余”于2008年2月14日入院。患者2个月前无明显诱因出现腹胀，腹围逐渐增加，伴纳差、消瘦，无腹痛、恶心、呕吐、皮肤巩膜黄染，无浮肿、尿量减少、发热、乏力、盗汗。大便正常，褐软便，每日1次。既往高血压10余年，未规律服药。吸烟10年，10支／d，已戒15年。入院查体：体温36．5℃，脉搏98次／min，呼吸21次／min，血压120／70mmHg（1mmHg=0.133kPa）。一般情况可，未见肝掌、蜘蛛痣。浅表淋巴结未触及肿大。颈静脉充盈，肝颈静脉回流征（一）。双肺呼吸音清，未闻干湿哆音。心界正常，心率98次／min，律齐，各瓣膜听诊区未闻及杂音。腹膨隆，腹围107cm，腹壁静脉显露，脐上与脐下静脉血流均自下向上。腹壁张力稍大，全腹无压痛、反跳痛，未触及包块，肝脾触诊不清，全腹叩诊浊音，肠呜音减弱。双下肢无浮肿。四肢肌力正常，双侧病理征（一）。
Pre-clinical development of the human CD40 agonistic antibody ADC-1013
Authors: Per Norlén, Niina Veitonmäki, Karin Smith, Thomas H Tötterman, Sara M Mangsbo, Christina Furebring, Peter Ellmark
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Activation of CD40 on dendritic cells increases cross-presentation of tumor antigens and as a result the number of activated tumor directed T effector cells. CD40 agonists have been shown to generate powerful systemic anti-tumor responses when administered in situ. The pre-
A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter
Authors: G. Agnelli, M. Verso, S. Bertoglio, W. Ageno, M. Bazzan, P. Parise, S. Salvagni, E. Naglieri, A. Santoro, A. Lazzaro
Journal: Journal of Clinical Oncology (2004)

8021
Ultrastructure of N-Nitrosodibutylamine-Induced Tumors of the Nasal Cavity in the European Hamster2
Authors: Hildegard Reznik-Schüller, Ulrich Mohr
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Ultrastructure of N-Nitrosodibutylamine-Induced Tumors of the Nasal Cavity in the European Hamster Get access Hildegard Reznik-Schüller, Hildegard Reznik-Schüller Search for other works by this author on: Oxford Academic PubMed Google Scholar Ulrich Mohr Ulrich Mohr Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 57, Issue 2, August 1976, Pages 401–407, https://doi.org/10.1093/jnci/57.2.401 Published: 01 August 1976 Article history Received: 02 December 1975 Accepted: 13 February 1976 Published: 01 August 1976
Dependency of Sister Chromatid Exchange in T- and B-Cells on the Incorporation of Deoxyribonucleosides Into Chromosomal DNA 2
Authors: Yukimasa Shiraishi, Herbert Weinfeld, Jun Minowada, Avery A. Sandberg
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Dependency of Sister Chromatid Exchange in T- and B-Cells on the Incorporation of Deoxyribonucleosides Into Chromosomal DNA Get access Yukimasa Shiraishi, Yukimasa Shiraishi Search for other works by this author on: Oxford Academic PubMed Google Scholar Herbert Weinfeld, Herbert Weinfeld Search for other works by this author on: Oxford Academic PubMed Google Scholar Jun Minowada, Jun Minowada Search for other works by this author on: Oxford Academic PubMed Google Scholar Avery A. Sandberg Avery A. Sandberg 4 3Roswell Park Memorial Institute, 666 Elm Street, Buffalo, N.Y. 14263 4Dr. Avery A. Sandberg. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 57, Issue 6, December 1976, Pages 1217–1224, https://doi.org/10.1093/jnci/57.6.1217 Published: 01 December 1976 Article history Received: 25 February 1976 Revision received: 10 May 1976 Published: 01 December 1976
Leukemia following treatment of germ cell tumors in men.
Authors: J R Redman, D Vugrin, Z A Arlin, T S Gee, S J Kempin, J H Godbold, D Schottenfeld, B D Clarkson
Journal: Journal of Clinical Oncology (1984)

We investigated the incidence of leukemia occurring subsequent to the treatment of germ cell tumors in men at our institution over a 30-year interval and found four patients with acute nonlymphocytic leukemia (ANLL) and one patient with chronic myelomonocytic leukemia. The relative risk (observed/expected cases) estimates for the development of leukemia ranged from 13.7 (P = .0005) in the total population to 50.1 (P = .0001) in the group treated with cytotoxic agents alone. All three patients with ANLL treated with contemporary antileukemic therapy had complete responses, with survivals of 7, 29, and 133 + months. In a review of the literature, 14 additional cases of germ cell tumors were found in which the men subsequently developed leukemia. It is concluded that leukemia following germ cell tumors is increased in incidence and is likely to be treatment induced. Complete responses and long-term survival are possible in secondary leukemia and aggressive antileukemic therapy should be given.
Rare epidermal growth factor receptor (EGFR) mutations in 10,117 patients with non-small cell lung cancer (NSCLC) evaluated by the French ERMETIC IFCT network: Clinical, molecular, and survival data.
Authors: Michele Beau-Faller, Nathalie Prim, Anne-Marie Ruppert, Isabelle Nanni, Benjamin Besse, Fabienne Escande, Sarab Lizard, Jean-Luc Pretet, Patricia DE Cremoux, Florence DE Fraipont, Isabelle Rouquette, Jerome Solassol, Yvan Bieche, Anne Cayre, Anne-Claire Voegeli, Elisabeth Quoix, Franck Morin, Helene Blons, Jacques Cadranel
Journal: Journal of Clinical Oncology (2012)

10507 Background: The EGFR exon 19 deletion and exon 21 L858R mutation are associated with response to EGFR-TKI. However, the correlation with response to EGFR-TKI remains unclear for rare exon 18 and 20 EGFR mutations. We investigated the clinical features of NSCLC patients with exon 18 and exon 20 EGFR mutations, analyzed response to EGFR-TKI and patient's survival. Methods: Between 2005 and 2011, all rare exon 18 and 20 EGFR mutations were collected from 10117 cases of NSCLC in 15 of 28 French NCI molecular genetic laboratories. Results: During the study period, EGFR mutations were identified in 1048 (10.35%) out of the 10117 performed tests and 108 rare mutations (10.3%) were identified in 103 patients, including 25 never identified mutations. Among them, 48 mutations were localized at exon 18 and 60 at exon 20, with 3 out of the 4 identified T790M exon 20 mutations associated with L858R mutation. Only 5 other rare mutations were associated with EGFR 19 or 21 mutations. 38 patients received EGFR-TKI (erlotinib, n=32; gefitinib, n=6). Among the 36 evaluable patients, best response on TKI was progression in 18 patients (50%), stabilization in 11 (30.5%) and partial response in 7 (19.4%). Tumor control rate observed in exon 18 mutations was 61% (8/13) and 50% (13/26) in exon 20 mutations. For the EGFR-TKI treated patients, the median PFS was 6 months (2-53). Median OS was 15 months (1-92), with no difference between the EGFR-TKI treated patients or not. Conclusions: Prevalence of rare EGFR mutations was 1.06% of all tested NSCLC and 10.35% of all EGFR mutations. Tumor control on TKI was observed in half of the patients. Reports of NSCLC harboring rare mutations are important to help the decision-making process in this subset of patients.
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
Authors: George G. Zhanel, Doris Cheung, Heather Adam, Sheryl Zelenitsky, Alyssa Golden, Frank Schweizer, Bala Gorityala, Philippe R. S. Lagacé-Wiens, Andrew Walkty, Alfred S. Gin, Daryl J. Hoban, James A. Karlowsky
Journal: Drugs (2016)